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Chapter 1: Introduction
1.1 RELEVANCE OF E-CIGARETTES
Electronic nicotine delivery systems, also known as e-cigarettes, have been developed to
allow nicotine vapor consumption and assist individuals with smoking cessation from
conventional tobacco cigarettes (Caponnetto, Russo et al. 2013, Cai and Wang 2017). However,
recent rises in recreational e-cigarette use have been attributed to individuals who have not
previously engaged in traditional cigarette use due to their well-known negative health effects
(Javadi-Paydar, Kerr et al. 2019). According to the CDC, increased marketing and versatile
flavorings of e-cigarettes has also led to increased recreational usage of these systems, especially
among the adolescent and young adult population (Singh, Arrazola et al. 2016, Cai and Wang
2017, Cullen, Liu et al. 2019, Bandi, Cahn et al. 2021). Recent reports on e-cigarette use have
shown that while adult use in the U.S. has increased modestly from 3.0% in 2017 to 4.5% in 2019
(Wang, Asman et al. 2018, Cornelius, Wang et al. 2020), a dramatic increase in adolescent use has
been observed, with use in this population increasing from 11.7% in 2017 to 27.5% in 2019 (Bold,
Kong et al. 2021). This increase in the recreational use of e-cigarettes is alarming considering the
well-known addictive properties of nicotine and highlight the need for research on this novel
nicotine delivery system (Cai and Wang 2017).
1.2 NICOTINE ABUSE LIABILITY
Addiction to drugs of abuse, such as nicotine, is a complex disease that is characterized by
many components. Koob and Le Moal (2001) describe an addiction cycle that is comprised of
three major components: preoccupation-anticipation, binge-intoxication, and withdrawal-negative
affective states. Importantly, the authors note that different drugs and patterns of use can result
in differences in the intensity of each component of the addiction cycle. One recent study
1

investigated the abuse liability (i.e., tendency to use the drug excessively) of e-cigarettes against
Food and Drug Administration approved nicotine inhalers and users’ own brand of traditional
cigarettes. This study found that e-cigarette abuse liability was higher than that seen with nicotine
inhalers, but lower than that observed with traditional cigarettes (Maloney, Breland et al.
2019). Additionally, comparable plasma nicotine levels following exposure to the highest nicotine
concentration against traditional cigarettes suggests the potential for nicotine dependence with
repeated e-cigarette use.
1.3 NICOTINE WITHDRAWAL
Increases in drug intake and withdrawal, following repeated nicotine exposure via
intravenous self-administration and osmotic mini pumps has been well documented in pre-clinical
models, particularly rodents (O'Dell, Chen et al. 2007, Flores, Cruz et al. 2020). Research with rats
has also shown that repeated nicotine exposure may also result in neuroadaptations that underlie
long-term increases in drug intake and withdrawal (Berke and Hyman 2000). A recently published
study reports important initial steps for characterizing the effects of nicotine vapor on drug intake
and withdrawal. In this study researchers demonstrated that previous exposure to nicotine vapor
during adolescence results in an increased propensity to self-administer nicotine later in adulthood
through intravenous self-administration (Kallupi, de Guglielmo et al. 2019). The authors also go
on to demonstrate that while spontaneous withdrawal from nicotine vapor did not increase anxiety
levels as indicated by the elevated plus maze, increases in somatic withdrawal signs were observed
(Kallupi, de Guglielmo et al. 2019). Together, these findings demonstrate that nicotine vapor
exposure in rodents, results in addictive behaviors similar to those seen following more traditional
routes of exposure and calls for further characterization of the effect of nicotine vapor on the brain
and behavior.
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1.4 BRAIN STIMULATION REINFORCEMENT
While there are a number of drug-induced neuroadaptations that are believed to drive
changes in drug intake and withdrawal, aberrant dopamine signaling in the brain reward system is
perhaps the most well defined (Koob and Le Moal 2005, 2008). Drug effects on the brain reward
system can be studied in rodents by using Intracranial Self-Stimulation (ICSS) of the mesolimbic
dopamine reward pathway that projects from the ventral tegmental area to the nucleus
accumbens. ICSS allows animals to deliver electrical stimulations to brain reward structures
through a response manipulandum. Stimulating electrodes are aimed at specific structures of the
brain reward pathway, including the medial forebrain bundle (MFB), a relatively larger section of
the mesolimbic pathway (Carlezon and Chartoff 2007). Electrical stimulations to the MFB are
often measured in amplitudes and amplitudes that produce high rates of responding are presumed
to reflect general brain reward thresholds. Electrical stimulation of the brain reward pathway with
ICSS does indeed reinforces response behavior and this technique is often used to investigate the
effects of drug exposure on the brain reward system.
Stimulation threshold baselines can be established for individual subjects and changes in
these thresholds after drug administration have been assessed to determine increases or decreases
in brain reward sensitivity (Markou and Koob 1992). Specifically, Koob and his colleagues
suggest that elevations in ICSS reward thresholds relative to baseline reflect decreases in reward
sensitivity observed during negative psychological states, such as those seen with withdrawal.
Conversely, decreases in ICSS thresholds relative to baseline may suggest increases in brain
reward sensitivity, such as that seen immediately following drug intake (see Figure 1). Studies
have indeed demonstrated decreases in ICSS thresholds immediately following nicotine injections
and increases in ICSS threshold during withdrawal from repeated nicotine injections (Johnson,
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Hollander et al. 2008, Fowler, Tuesta et al. 2013). Identifying brain reward threshold changes
during and after nicotine vapor exposure will be an important step towards characterizing the
biological and behavioral effects of this new and highly popular nicotine delivery system.
1.5 OBJECTIVES
Experiment 1: This experiment investigated the effects of repeated nicotine vapor exposure on
somatic withdrawal signs and anxiety-like behavior in rats. Withdrawal in human users of
traditional nicotine products is well described, therefore examining withdrawal behaviors
following vapor exposure is a necessary first step for nicotine vapor research.
Experiment 2: This experiment investigated the effects of acute and repeated nicotine vapor
exposure on brain reward function. More specifically, this experiment assessed the effects of
nicotine vapor exposure and withdrawal on ICSS brain reward thresholds in rats. Findings will
provide valuable insight on how nicotine vapor can affect the brain reward system.

4

Chapter 2: Methods
2.1 SUBJECTS
Adult male Sprague-Dawley rats (n=56) and male Wistar rats (n=16) were obtained from
an outbred stock of animals (Envigo Inc., Indianapolis, IN) for Experiment 1 and Experiment
2, respectively. Animals in both experiments were housed in a humidity and temperaturecontrolled vivarium (22°C) with a 12hr light/dark cycle and ad libitum access to food and water,
except as noted below. Animals in Experiment 1 will be pair-housed, while animals in Experiment
2 will remain individually housed to minimize electrode implant displacement. All experiments
were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at the
University of Texas of El Paso.
2.2 APPARATUS
Nicotine vapor system: A Four Chamber Benchtop Passive E-vape Inhalation System (La
Jolla Alcohol Research Inc., San Diego, CA) was used to deliver nicotine vapor to animals in both
experiments. The system is composed of four chambers large enough to house two rats per
chamber (interior dimension of 14.5" L x 10.5" W x 9.0" H). Each chamber has two valve ports
that are located on opposite walls and allow connection to vapor tubing. One valve port was
connected via PVC tubing to a small vacuum that provided airflow in the chamber at 0.6 L per
minute. The vacuum outlet was connected to a Whatman HEPA filter (Millipore Sigma,
Darmstadt, Germany), then onto a building exhaust system that safely removed the nicotine vapor
from the chambers. The other valve port was connected via PVC tubing to a TFV4 mini-tank (4.9volt, 65.0W; Smok Inc, Shenzhen, China), where the nicotine e-liquid was heated by a 0.42 Ω
atomizer coil. Each nicotine concentration and vehicle control (24 mg/mL, 12 mg/mL, and 0
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mg/mL) is assigned its own tubing and exposure chambers are thoroughly cleaned between
exposures to avoid cross-contamination between experimental groups.
Operant chambers: Operant chamber (12” L x 9.5” W x 11.5” H, Med-Associates, Inc.,
Fairfax, VT) used in Experiment 2 were Plexiglas boxes with grid flooring, houselights, and a
fixed wheel manipulandum attached to a wall of the Plexiglas box. The wheel manipulandum is
used to deliver electrical brain reward self-stimulations. A stimulator provides electrical
stimulations that are sent through a commutator (2-channel, 305-plugs) located in each operant
chamber. The commutator is attached to a commutator balance arm (0-20.3 cm, above chamber).
A spring leash (5-100 cm, 2-channel; PTechnologies, Roanoke, VA) is screwed onto the
commutator on one end and an electrode pedestal implanted into the animal on the other. A
modified top permits the animal to move freely during training.
Elevated plus maze: The elevated plus maze (EPM) was used in Experiment 1 to assess
anxiety-like behavior, as a measure of withdrawal. The EPM consists of two closed arms and two
open arms (10 cm W x 50 cm L). The closed arms had walls that were 20 cm in height and the
maze was elevated 50 cm from the ground. All EPM testing was conducted under a red light, as
differences in light exposure may influence behavior when using the elevated plus maze.

2.3 DRUGS
The present study used flavorless nicotine e-liquids containing nicotine in its freebase form
in a 50/50 vegetable glycerin/propylene glycol vehicle. All nicotine e-liquids were purchased from
the commercial vendor Vapor Chef (VC Tobacco #13; Bristol, PA). Nicotine e-liquid
concentrations of 24 mg/mL and 12 mg/mL, as well as a 0 mg/mL nicotine vehicle control were
used for Experiment 1, while 0 mg/mL or 24 mg/mL were used for Experiment 2. For Experiment
1 injections of nicotine ditartrate salt (0.8 mg/kg, s.c., expressed as a base) and the non-selective
6

nicotinic receptor antagonist mecamylamine (3.0 mg/kg, s.c., salt) were used (National Institute
on Drug Abuse; Bethesda, MD). Both of these drugs were dissolved in 0.9% sterile saline and the
pH of nicotine ditartrate salt was adjusted to 7.4 using a pH meter with chloride and hydroxide
titration.
2.4 PROCEDURES FOR EXPERIMENT 1
Nicotine vapor exposure: Animals were allowed to acclimate to the vivarium for at least 1
week prior to nicotine vapor exposures. Once acclimated, animals began 9 consecutive days of
experimental procedures (see Figure 2 for a schematic of Experiment 1 timeline). Experiment 1
had a total of seven experimental groups (n=8/group) divided as: home cage (HC), vapor chamber
(VC), 0 mg/mL vehicle control, 12 mg/mL nicotine vapor, 24 mg/mL nicotine vapor, 0.8 mg/kg
nicotine injection, and saline injection. The HC group remained in their home cages for the entirety
of the experiment, while the vapor chamber group was placed in vapor chambers without any vapor
exposure.
For daily vapor exposures, animals with vapor exposure were placed in chambers with their
respective cage mate. Pseudo-randomized assignment to vapor exposure groups was used due to
the paired housing and exposure of the animals. The total time of nicotine vapor exposure sessions
for Experiment 1 and 2 was 89 minutes for each nicotine concentration. Each session consisted of
four cycles that lasts eighteen minutes and thirty seconds with an additional five-minute interexposure interval between each cycle. A 3-second nicotine puff is delivered into each chamber at
the beginning of a cycle followed by a two-minute inter-puff interval, for a total of ten 3-second
puffs every cycle. To model average daily nicotine vapor consumption in human e-cigarette users,
a total forty puffs were delivered to the rats per daily nicotine vapor exposure sessions (Qasim,
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Karim et al. 2018). To help minimize nicotine contamination, lower nicotine concentration groups
underwent vapor exposure before higher concentration groups during daily exposure sessions.
Tail blood collection: To confirm systemic absorption of nicotine using our nicotine vapor
inhalation system, tail blood (.5 mL) was collected for each nicotine concentration on exposure
day 6. This ten-minute procedure included brief anesthetization of each animal using 2.5-3%
isoflurane gas in oxygen. Blood was collected using Eppendorf vials and centrifuged at (6900 r. p.
m. x 4°C), before blood serum extractions were collected in separate vials and stored in a
collection box placed in a -80°C freezer. Post-surgical topical analgesics were applied to the tail
after sample collection. Cotinine detection was assessed utilizing an ELISA kit (Cal Biotech Inc,
El Cajon, CA), allowing for duplicate of the same sample. All standards, reagents, and substrate
amounts were determined based on instructions provided in the ELISA kit.
Withdrawal sign measures: On Day 7 of nicotine vapor exposure somatic signs were
measured in all animals. Animals were placed in a Plexiglas box (30cm x 29 cm) for assessment
of somatic signs. Following acclimation to the box, rats were injected with mecamylamine (3.0
mg/kg, s.c.) and an additional ten-minute waiting period was required before precipitated
withdrawal sign assessment. Number of somatic signs were recorded for ten minutes based on the
following list of known indicators of withdrawal: blinks, yawns, teeth chatters, gasps,
writhes, body shakes, headshakes, ptosis, and grooming (Harris, Pentel et al. 2011, Flores, Cruz et
al. 2020).
Elevated plus maze (EPM): On Day 9 of vapor exposure, anxiety-like behavior, reflected
by entries in the EPM, was assessed in all animals. Animals acclimated to the testing room in their
home cage for ten minutes, followed by an injection of mecamylamine (3.0 mg/kg, s.c.; Harris,
Pentel et al. 2011). As with somatic sign assessment, a ten-minute waiting period following
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mecamylamine administration was required before placing animals in the middle of the EPM,
facing an open arm. Assessment of behavior during precipitated withdrawal was based on closed
versus open arm entries, across five minutes.
2.5 PROCEDURES FOR EXPERIMENT 2
Electrode implantation: Animals were anesthetized using isoflurane 2.5-5% gas in oxygen.
Once anesthetized, rats were administered an intraperitoneal injection of saline (3.0 ml), a
subcutaneous injection of flunixin (0.2 ml), and a subcutaneous injection of lidocaine on the scalp
(0.1 ml). Animals were then positioned and secured in a stereotactic frame, with a flat skull
position established by matching dorsal-ventral coordinate measures. Following screw
placements, a 5mm incisor bar elevation was applied, and a unilateral untwisted electrode was
implanted into one hemisphere (left and right hemisphere, counterbalanced) with the tip of the
electrode targeting the medial forebrain bundle (MFB) at the level of the lateral hypothalamus
(AP: -0.5 mm from bregma; ML: +- 1.7 mm; DV: -9.3 mm from the skull surface; Paxinos &
Watson, 2007). After electrode placement, 2-3 screws were secured with acrylic cement glue to
create a “cap” around the surgical site. Postsurgical analgesics (i.e. Neosporin) were administered
according to institutional regulations. Rats recovered from surgery for 5-7 days before any
behavioral training was initiated.
ICSS training: Following recovery from surgery, animals began training in the ICSS task
(see Figure 3 for a schematic of Experiment 2 timeline). In phase I of training, animals were tested
individually in ICSS operant chambers. All animals started training with a default stimulation
frequency of 100Hz and 120 microamperes (µA), which were delivered freely following ¼
rotations of the response wheel. If low wheel responding was observed in an animal after
approximately 5 minutes, 10-20 µA adjustments were made to the ICSS stimulation within
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sessions. Animals were trained in phase I until the criteria of 100 spins of the response wheel was
achieved within 5 minutes.
For phase II training, trials begin with a noncontingent stimulation, followed by a variable
post-stimulation response window (7.5 s) during which delivery of a second stimulus was
contingent upon a ¼ turn of the response wheel. Animals were required to spin the response wheel
for 30 contingent electrical stimulations, at 5 different inter-trial intervals (ITI). ITIs were
presented in ascending order (1, 3, 5, 10, and 15 sec), with one ITI assigned per day. Noncontingent and contingent stimulations were matched and daily sessions began with µAstimulations that produced successful responding on the previous training day. If low wheel
responding was observed in an animal during a session, 10-20 µA adjustments were made to the
stimulations for the following training sessions.
In phase III we attempt to identify µA thresholds that produced maximal responding to
non-contingent stimulations in individual rats. To determine these thresholds, µA thresholds
“blocks”, consisting of 3 trials per block, were automatically adjusted within daily session by the
MedPC program based on each animal’s responding to the non-contingent stimulus. When no
response was detected for 2 out the 3 trials at a given µA-block, the stimulation increased by 5µA.
When responding was detected for 2 out the 3 trials at a given µA-block the stimulation decreased
5µA. In each daily session, 2 descending and 2 ascending µA-block series were presented, starting
with a descending session and progressing in an alternating manner. The threshold for each of the
4 series was defined as the midpoint between the two µA-blocks immediately preceding a shift in
series order. For phase III training day 1, the starting µA-setting was based on the last µA-setting
successfully presented on the last day of phase II. On all subsequent phase III training days, the
starting µA-setting was based on the average of the 4 identified series thresholds, plus 30 µA. If
10

an animal maintains responding for 4 to 5 days on phase III they were moved to phase IV. If
responding is not maintained across 4 to 5 days on phase III, they were returned to phase II training.
Phase IV followed the same procedures used in phase III training. During phase IV, the
average of the four alternating µA-block series is identified as the rat’s threshold for that day. This
phase ended when all thresholds were stable, meaning that there was less than 10% variability of
amplitude increases and decreases across 3 training days. Response latencies were also identified
and defined as the point between the start of the non-contingent stimulus and a ¼ turn response on
the wheel (Chellian, Wilks et al. 2021).
Nicotine vapor exposure: Once rats achieved stability criteria for phase IV, they were
pseudo-randomly assigned into one of two groups 0 mg/mL vehicle control or a 24 mg/mL nicotine
vapor concentration (n=8/group) and underwent 14 consecutive days of vapor exposure
immediately prior to ICSS testing, using daily vapor exposure parameters described in the
Procedures section for Experiment 1. On day 1 of exposure, acclimation to vapor chambers was
achieved by placing the rats in the chambers (without vapor) for 30 minutes before vapor exposure
began.
ICSS threshold testing: Animals were tested in ICSS using procedures described for Phase
IV training. Testing occurred immediately following each day of the 14 days of nicotine vapor
exposure and for an additional 14 days following nicotine vapor exposure cessation. This approach
allowed us to assess the effects of acute and repeated nicotine vapor exposure, and spontaneous
withdrawal from repeated nicotine vapor exposure, on ICSS brain reward thresholds.
Histology: Whole brains were collected following decapitation on withdrawal day 14,
following ICSS testing, for electrode placement verification. Brains were stored for 3-4 days in
4% PFA diluted using 1X PBS, then placed in a 30% sucrose/70% PFA solution for 6 days. Brains
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were sliced at 40 µm using a cryostat and tissues were mounted on gelatin-coated slides. Tissues
were dehydrated using distilled water, followed by increasing concentrations of ethanol (i.e., 50,
70, 95, and 100%, 3 min each) for compatibility with xylene (Thermo Fisher Scientific, Waltham,
MA). Tissues were then gradually rehydrated through descending concentrations of ethanol
(i.e.,100, 95, 70, and 50%, 3 min each) before staining by dipping tissues in thionine (Thermo
Fisher Scientific, Waltham, MA). Tissues were again dehydrated through ascending ethanol
concentrations and xylene for compatibility with mounting medium, and left to dry. A line of DPX
was placed across slides, which were then sealed with a coverslip and left to dry overnight. TIFFformatted images were taken using a bright-field microscope with an x5 magnification (Carl Zeiss
Corporation, Thornwood, NY) and an EXi monochrome camera (TeledyneQimaging, Inc., Surrey,
British Columbia) with Volocity Software (Ver. 6.1.1; Quorum Technologies, Inc.,Puslinch,
Ontario).
2.6 STATISTICS
Statistical analyses used in Experiment 1 included a one-way ANOVA with LSD post-hoc tests
for cotinine, somatic withdrawal signs, and entries. Statistical analysis for Experiment 2 included
mixed-model ANOVAs with t-tests post-hoc analysis for response latencies, threshold µAsettings, and threshold percent changes from baseline (average of last 3 days of Phase IV training
thresholds for nicotine vapor exposure and average of last 3 days of nicotine vapor exposure
thresholds for nicotine vapor withdrawal). Bonferroni post-hoc tests were also conducted for all
analyses and significant LSD and t-tests that were also found to be significant with Bonferroni are
denoted with an asterisk (*).
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Chapter 3: Results
3.1 EXPERIMENT 1
3.1.1 Blood plasma cotinine levels
Figure 4 illustrates blood plasma cotinine levels from tail vein blood that was extracted
from all groups following 6 days of nicotine vapor exposure. One-way ANOVA revealed a main
effect of group [F =157.58; p<0.001]. Post-hoc analyses show that rats in the 12 mg/mL and 24
(6,49)

mg/mL nicotine vapor groups expressed higher cotinine levels than HC, VC, 0 mg/mL, and saline
injection groups (p <0.001*). Similarly, post-hoc tests revealed significantly higher cotinine levels
s

in the 0.8 mg/kg nicotine injection group when compared to the saline injection group (p<0.001*).
When comparing groups exposed to nicotine vapor exposure to group exposed to nicotine
injections, post-hoc analyses show that the 12 mg/mL group had significantly lower cotinine levels
(p<0.001*), while the 24 mg/mL group had higher cotinine levels, than the 0.8 mg/kg nicotine
injection group (p<0.001*). Finally, a comparison of cotinine levels between the 12 mg/mL
nicotine vapor group and 24 mg/mL nicotine vapor group showed that the 24 mg/mL group had
significantly higher cotinine levels than the 12 mg/mL group (p<0.001*), following 6 days of
vapor exposure. In summary, higher nicotine concentration exposure resulted in increased levels
of cotinine when compared to animals in control groups.
3.1.2 Somatic signs of withdrawal
Figure 5 illustrates somatic signs that were assessed in all groups on day 7 of nicotine vapor
exposure, following mecamylamine administration. A one-way ANOVA revealed a main effect of
exposure group [F( =3.84; p<0.003]. Post-hoc analyses revealed that the 12 mg/mL and 24
6,49)

mg/mL nicotine vapor group displayed more somatic signs when compared to the HC group
(p<0.005, p<0.001*, respectively). The 24 mg/mL nicotine vapor group was also found to display
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more somatic signs than saline injection, VC, and 0 mg/mL vehicle control groups (p<0.05). These
findings demonstrate that increases in somatic withdrawal signs were displayed in animals exposed
to higher nicotine concentrations when compared to controls.
3.1.3 Elevated plus maze open arm entries
Figure 6 illustrates anxiety-like behavior that was assessed in all groups on day 9 of
nicotine vapor exposure, following mecamylamine administration. A one-way ANOVA revealed
a main effect of treatment group [F =2.38; p<0.05]. Post-hoc analysis revealed that the 24 mg/mL
(6,49)

nicotine vapor group had fewer open arm entries than the HC group (p<0.05) and that the 0.8
mg/kg nicotine injection group had fewer open arm entries when compared to the saline injection
group (p<0.05). Results in the EPM test show that exposure to higher nicotine concentrations
resulted in fewer open arm entries in the EPM when compared to the control group.
3.2 EXPERIMENT 2
3.2.1 ICSS Thresholds
Figure 7 illustrates ICSS threshold measures as µA values during the 14 days of nicotine
vapor exposure, as well as the 14 days immediately following cessation of nicotine vapor exposure.
Two rats from each treatment group were removed from the study, due to a failure to complete
ICSS training or electrode dislodgement during the training, resulting in a final total of 6 rats per
group. Mixed-model ANOVA comparing nicotine vapor exposure groups across the 14 days of
treatment revealed a main effect of time [F(

13,126)

=1.84; p<0.05], such that all rats exhibited a slight

increase in threshold across the 14 days of treatment (Figure 7A). No main effect or interaction
was observed for treatment group during nicotine vapor exposure days. Mixed-model ANOVA
comparing nicotine vapor exposure groups across the 14 days immediately following cessation of
nicotine vapor exposure revealed no main effect or interaction for either time or treatment group
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(Figure 7B). Overall, thresholds between vehicle control and 24mg/mL nicotine concentration,
were comparable immediately following daily exposure to vapor. During withdrawal days
thresholds between 0 mg/mL vehicle control and 24 mg/mL again remained similar.
3.2.2 ICSS Thresholds Percent Change
Figure 8 illustrates ICSS thresholds measures as percent change from baseline during the
14 days of nicotine vapor exposure, as well as the 14 days immediately following cessation of
nicotine vapor exposure. Mixed-model ANOVA comparing nicotine vapor exposure groups across
the 14 days of treatment revealed no main effect or interaction for time or treatment group (Figure
8A). Mixed-model ANOVA comparing nicotine vapor exposure groups across the 14 days
immediately following cessation of nicotine vapor exposure revealed a main effect of group
[F( =11.01; p<0.01]. No main effect or interaction was observed for time during days
1,10)

immediately following cessation of nicotine vapor exposure. Post-hoc analysis comparing the
nicotine vapor treatment groups on each day immediately following cessation of nicotine vapor
exposure revealed higher percent changes in the 24 mg/mL nicotine vapor exposure group, when
compared to the 0 mg/mL vehicle control group, on days 1, 3, 8, 9, and 13 (p <0.05, Figure 8B).
s

In summary, thresholds expressed as percent change were comparable in the 0 mg/mL vehicle
control and 24 mg/mL nicotine concentration groups immediately following daily vapor exposure.
Interestingly, thresholds during withdrawal days were significantly different between 0 mg/mL
vehicle control and 24 mg/mL nicotine concentration groups, with the 24 mg/mL nicotine
concentration group displaying higher threshold percent changes when compared to the 0 mg/mL
vehicle control group.
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3.2.3 Response latencies
Figure 9 illustrates ICSS response latencies during the 14 days of nicotine vapor exposure,
as well as the 14 days immediately following cessation of nicotine vapor exposure. Mixed-model
ANOVA comparing nicotine vapor exposure groups across the 14 days of nicotine vapor exposure
revealed no main effect or interaction for time or treatment group (Figure 9A). Similarly, mixedmodel ANOVA comparing nicotine vapor exposure groups across the 14 days immediately
following cessation of nicotine vapor exposure revealed no main effect or interaction for time or
treatment group (Figure 9B). These findings suggest that exposure to 24 mg/mL nicotine does not
significantly increase ICSS response latencies when compared to the 0 mg/mL vehicle controls.
3.2.4 Electrode placement verification
Figure 10 illustrates ICSS electrode placement in the MFB for all rats, as plotted onto
figures of a rat brain atlas (Paxinos & Watson, 2007). Gross observations of electrode placement
suggest that of the 12 rats completing ICSS training and test, 7 rats had placement in the MFB,
with 3 rats having electrode placements just outside of the MFB (2 from the 0 mg/mL vehicle
control group and 1 from the 24 mg/mL vapor group) and 2 rats did not have electrode placement
confirmed (1 from the 0 mg/mL vehicle control group and 1 from the 24 mg/mL vapor group).
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Chapter 4: Discussion
The findings of my thesis demonstrate that our novel nicotine vapor system creates
significant withdrawal-like states in male rats following cessation of repeated nicotine vapor
exposure. Our model produced somatic withdrawal signs and anxiety-like behavior, similar to
those observed with more well-established routes of nicotine administration in rodents. Effects of
nicotine vapor exposure on the brain reward system was also assessed and findings demonstrate
brain reward changes through relative increases in brain reward stimulation thresholds.
Specifically, increases in ICSS brain reward thresholds’ percent change was observed following
cessation of repeated nicotine vapor exposure (i.e., nicotine withdrawal).
Increased cotinine biomarkers observed following nicotine vapor exposure: A major
nicotine metabolite, cotinine, has a longer half-life (15-19 hours) compared to nicotine (2-3 hours),
and other plasma nicotine biomarkers (Benowitz 1996, Buccafusco and Terry 2003, Avila-Tang,
Al-Delaimy et al. 2013). This characteristic makes cotinine detection reliable for assessment of
nicotine vapor exposure. Findings from Experiment 1 show that exposure to nicotine vapor (12
and 24 mg/mL) did indeed increase cotinine levels relative to negative controls on day 6 of
exposure. When comparing animals in the 24 mg/mL group to animals in the 12 mg/mL group, we
found that the group with the higher concentration of nicotine also had higher levels of cotinine,
as expected. Additionally, we found that when compared to the group receiving 0.8 mg/mL
nicotine injections across treatment days, the 24 mg/mL vapor group had slightly higher cotinine
levels, and the 12 mg/mL group had slightly lower cotinine levels. The 0.8 mg/kg dose was
selected as a positive control as it is considered a moderate injection dose of nicotine that has been
shown to produce cotinine levels in rats similar to those seen in in traditional cigarette smokers
(Vieira-Brock, Andrenyak et al. 2013, Allen, Wasserman et al. 2019). While the nicotine e-liquid
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concentrations used in our experiment produce cotinine levels that were slightly outside of the
range produced by the 0.8 mg/kg injection, they did produce cotinine levels comparable to those
observed when using other traditional doses and routes of administration (Shoaib and Stolerman
1999, Torres, Gentil et al. 2013, Craig, Zhao et al. 2014), as well as cotinine levels observed in
human e-cigarette users (Flouris, Chorti et al. 2013, Marsot and Simon 2016). Others have
demonstrated that the use of passive nicotine vapor exposure in rodents also effectively models
pharmacokinetics related to behavioral and metabolic changes in human e-cigarette users (Shao,
Lopez et al. 2019). However, one limitation to consider with rodent vapor exposure, is the limited
control of total nicotine administered to the subjects. Systemic delivery of nicotine in animals via
vapor inhalation can indeed fluctuate based on subject size and inhalation rate, as well as location
within the vapor exposure chamber. Overall, the translational framework of the described rodent
vapor inhalation system can uniquely contribute to the literature on nicotine addiction by providing
a reliable and valid animal model of human e-cigarette consumption (Matta, Balfour et al. 2007).
Increased severity of withdrawal behavior observed following nicotine vapor exposure:
Increases in physical withdrawal and anxiety-like behavior following cessation of nicotine
exposure have been observed across animal species. Somatic behavioral signs of withdrawal have
been thoroughly characterized in rodents (Malin et al., 1992), while decreases of open arm entries
in an elevated plus maze are commonly assessed as a measure of anxiety-like behavior (Walf and
Frye 2007). In our studies, Experiment 1 assessed both somatic signs and open arm entries in an
elevated plus maze during precipitated withdrawal from repeated nicotine vapor exposure. The
results revealed that rats exposed to 24 mg/mL nicotine vapor yielded more somatic withdrawal
signs (e.g., blinks, yawns, writhes etc.) relative to those in all control groups, while rats exposed
to 12 mg/mL nicotine vapor yielded more somatic withdrawal signs relative to only those in the
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home cage control group. Similar evidence suggests that repeated exposure to nicotine using more
traditional routes of administration also leads to increases in somatic withdrawal signs (Skjei and
Markou 2003).
Regarding entries to the elevated plus maze open arms, analyses showed that animals
receiving 24 mg/mL nicotine vapor had significantly fewer open arm entries than animals that
were left in their home cages throughout the experiment. Decreases in open arm entries on an
elevated plus maze have previously been observed in mice exposed to other concentration of ecigarette vapor or to cigarette smoke (Ponzoni, Moretti et al. 2015). Interestingly, a more recent
study also showed decreases in open arm entries following nicotine vapor exposure in male and
female rats, despite a 3-week abstinence period between last day of vapor exposure and testing
(Smith, Kallupi et al. 2020), suggesting that nicotine induced anxiety-like behavior may be a longlasting characteristic observed during withdrawal. To our surprise, our model produced only
modest decreases in open arm entries when tested immediately following day 9 of nicotine vapor
exposure. Studies have shown that females display increases in anxiety-like behavior compared to
male rats on the EPM and these differences have been suggested to be mediated by ovarian
hormones and stress responses (Torres, Pipkin et al. 2015, Flores, Cruz et al. 2020). Similar results
have also been observed in female mice following chronic nicotine exposure (Caldarone, King et
al. 2008). Therefore, a limiting factor in the current study, possibly explaining the modest effect
of anxiety-like behavior observed, was that we did not include female rats in our investigation.
However, the EPM has shown to have face validity in its ability to measure anxiety in rodents,
reflected by avoidance into open vs closed arms of the maze. In the EPM the animals must choose
to enter into dark protected areas or into a lit open vulnerable space. Since rats are nocturnal
animals they naturally prefer the darker protected areas. Other behaviors displayed in open arms
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such as freezing, immobility and defecation are anxiety-related and increased in open arms
compared to closed arms (Pellow et al., 1985; Walf and Frye, 2007).
Increased brain reward thresholds observed following nicotine vapor exposure: Previous
research investigating the effects of nicotine exposure and withdrawal on brain reward function
using ICSS have administered nicotine using injections, minipumps, infusions, and smoke
exposure. In the current study we examine, for the first time, the effects of nicotine vapor exposure
and withdrawal on ICSS thresholds. Our analysis identified no significant changes in threshold
µAs or threshold percent change from baseline, during repeated nicotine vapor exposure. The
findings of the current study however, are not entirely surprising as previous literature examining
ICSS thresholds during nicotine exposure have produced mixed findings (Huston-Lyons and
Kornetsky 1992, Epping-Jordan, Watkins et al. 1998, Harrison, Gasparini et al. 2002, Chellian,
Wilks et al. 2021). The notion of variability in ICSS reward thresholds during nicotine exposure
may be due to differences in sample size per group, differences in methodology used between
experiments, and the resulting variation in pharmacokinetics. For example, differences in the
effects of nicotine delivery via osmotic minipumps on ICSS have been attributed to differences in
minipump infusion rates (Epping-Jordan, Watkins et al. 1998, Xue, Behnood-Rod et al. 2020). For
our experiment, a larger sample size per group could have helped reduce variability in this task.
Unlike previous work examining ICSS thresholds during nicotine exposure, previous
studies using ICSS has consistently shown elevations in reward thresholds in rats during nicotine
withdrawal, regardless of administration method (Watkins, Stinus et al. 2000, Kenny, Gasparini et
al. 2003, Muelken, Schmidt et al. 2015, Tan, Xue et al. 2019). Such effects have also been
displayed following cessation of other drugs of abuse classes that include, but are not limited to,
depressants, opiates and stimulants, (Schulteis, Markou et al. 1995, Chartoff, Sawyer et al. 2012,
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Holtz, Radke et al. 2015). As with previous reports on the effects of nicotine withdrawal on ICSS,
the current study revealed significant changes in thresholds during withdrawal from nicotine vapor
exposure. Furthermore, threshold elevations corroborate findings from Experiment 1, where our
nicotine vapor model was able to produce somatic signs and anxiety-like behavior during
precipitated nicotine vapor withdrawal.
No significant changes in response latencies were observed during or after repeated
nicotine vapor exposure in Experiment 2, suggesting that repeated nicotine vapor exposure does
not produce immediate or long-term increases in behavioral response time. The effects of nicotine
on response latencies in ICSS have produced mixed findings in previous work. For example, one
study found that increases in nicotine injection doses (0.125, 0.25, and 0.5mg/kg) produced no
effect in response latencies ICSS (Harrison, Gasparini et al. 2002). Alternatively, another more
recent study found that injection of nicotine significantly decreased response latencies (Xue,
Behnood-Rod et al. 2020). While increases in response latencies should be expected due to
nicotine’s well defined psychomotor stimulant effect, significant increases in response latencies
could represent performance effects resulting from nicotine’s stimulant effects, rather than effects
of nicotine on brain reward processes. Therefore, another potential limitation of the present study
is that locomotor activity was not directly assessed during ICSS training or testing sessions.
Assessment of activity during inter-trial intervals can help identify locomotor effects of nicotine
that are outside of contingent reward responding (Schaefer and Michael 1986). It is important to
note, however, that mixed results on locomotor activity do exist and are likely due to the
differences in rat strains, nicotine concentrations, nicotine’s biphasic locomotor effect, and route
and timeline of administration (Schaefer and Michael 1986, Samaha, Yau et al. 2005, Rauhut,
Zentner et al. 2008). For example, repeated intravenous infusions of 30µg/kg nicotine have been
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found to produce locomotor sensitization, while repeated peripheral injections of this same dose
resulted in tolerance to nicotine’s locomotor stimulant effect, suggesting that route of
administration plays a role in nicotine’s effects on activity (Lenoir, Tang et al. 2013).

22

Chapter 5: Conclusion
Future directions and conclusions: While the current study showed differences in
behavioral measures of withdrawal, it also highlights the need for further investigation of nicotine
vapor systems on both the brain and behavior. Future studies should investigate effects of ecigarette vapor in vulnerable populations, such as females, which display enhanced anxiety-like
behavior during nicotine withdrawal (Flores, Cruz et al. 2020). Additionally, a recent study
suggests that differences in intake patters of nicotine vapor between males and females may
underlie observed differences in cotinine levels (Lallai, Chen et al. 2021). Future work should also
include an assessment of the effects of nicotine vapor on adolescents, due to the dramatic increase
in e-cigarette use in this population and differences in nicotine withdrawal observed between
adolescent and adults (O'Dell, Bruijnzeel et al. 2006, Xue, Behnood-Rod et al. 2020). In addition
to investigating the effects of nicotine vapor exposure in specific populations, future studies should
continue to investigate the unique pharmacology of nicotine e-liquid and vaping behaviors,
including how different concentrations of nicotine, intake patterns, chemical additives (e.g., salt),
and chemical reaction products (e.g., nicotyrine) contribute to its effects on the brain and behavior
(Sleiman, Logue et al. 2016, Gholap, Kosmider et al. 2020).
The recent increase in e-cigarette use observed in adolescents and young adults is driven
by a shift in risk perception related to the negative health effects of e-cigarettes (Gorukanti,
Delucchi et al. 2017, Bandi, Cahn et al. 2021). The dramatic increase of e-cigarette use in these
populations highlights the immediate need for research on the effects nicotine vapor has on the
brain and behavior. This data is needed for the development of important educational campaigns
and regulation policies (Collins, Glasser et al. 2019). Additionally, while many traditional cigarette
smokers seek smoking cessation through e-cigarettes, studies have not provided clear evidence on
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whether these systems are effective for smoking cessation compared to other nicotine replacement
therapies (Pokhrel and Herzog 2015, Villanti, Feirman et al. 2018). A more thorough investigation
of the marketing, perceptions, and health effects of these novel nicotine delivery systems will be
required to better understand their long-term impact on society, and particularly, in vulnerable
populations.
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Figure 1. ICSS brain reward threshold changes during nicotine treatment and withdrawal.
Text in blue suggest differences in the presumed brain reward sensitivity, while text in red suggest
quantifiable changes in thresholds (commonly measured in µA or percent change in µA), following
intracranial self-stimulation behavior.
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Figure 2. Timeline for Experiment 1
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Figure 3. Timeline for Experiment 2
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Figure 4. Blood plasma cotinine levels following 6 days of nicotine vapor exposure.
Animals exposed to 12 and 24 mg/mL nicotine vapor, as well as 0.8 mg/kg nicotine injection
displayed significantly higher cotinine levels than home cage (HC), vapor chamber (VC), 0 mg/mL
(0), and saline injection (Sal) control groups. Asterisks (*) indicate significant difference from all
control groups and 24 mg/mL group, plus sign (+) indicates significant difference from all control
groups and 12 mg/mL group, and tilde (~) indicates significant difference from all control groups
and 0.8 mg/kg nicotine injection group. Critical p-value is 0.05.
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Figure 5. Total withdrawal signs following 7 days of nicotine vapor exposure.
Animals exposed to 24 mg/mL nicotine vapor displayed significantly more somatic signs than
home cage (HC), vapor chamber (VC), 0 mg/mL (0), and saline injection (Sal) control groups.
Animals exposed to 12 mg/mL nicotine vapor displayed significantly more somatic signs than
home cage (HC) control group. Asterisks (*) indicate significant difference from HC, VC, 0, and
Sal control group, while plus sign (+) indicates significant difference from HC control group.
Critical p-value is 0.05.
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Figure 6. Open arm entries in elevated plus maze following 9 days of nicotine vapor
exposure.
Animals exposed to 24 mg/mL nicotine vapor displayed significantly less open arm entries than
the home cage (HC) control group. Animals exposed to 0.8 mg/kg nicotine injections displayed
significantly more open arm entries than the saline injection (Sal) control group. Asterisks (*)
indicate significant difference from HC control group and tilde (~) indicates significant difference
from Sal control group. Critical p-value is 0.05.

30

Figure 7. ICSS thresholds in microamperes during nicotine vapor exposure and
withdrawal.
No significant differences in reward threshold microamperes were seen across 14 days of vapor
exposure (A) or across 14 days of withdrawal (B) when comparing animals exposed to 24 mg/mL
nicotine vapor (blue squares) to animals exposed to 0 mg/mL vehicle control (grey circles). Critical
p-value is 0.05.
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Figure 8. ICSS thresholds as percent change from baseline during nicotine vapor exposure
and withdrawal.
A) No significant differences were seen across 14 days of vapor exposure. B) Across 14 days of
withdrawal the 24 mg/mL nicotine vapor group (blue squares) displayed a significantly higher
threshold percent change from baseline than the 0 mg/mL vehicle control (grey circles). Up arrow
(^) indicates significant main effect of treatment group across 14 days nicotine vapor withdrawal
and asterisks (*) indicate significant difference between treatment groups on given day. Critical pvalue is 0.05.
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Figure 9. ICSS response latencies in seconds during nicotine vapor exposure and
withdrawal.
No significant differences in response latencies were seen across 14 days of vapor exposure (A)
or across 14 days withdrawal (B) when comparing animals exposed to 24 mg/mL nicotine vapor
(blue squares) to animals exposed to 0 mg/mL vehicle control (grey circles). Critical p-value is
0.05.
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Figure 10. ICSS electrode placement in the MFB.
Gross observations of electrode placement suggest that 7 rats had placement in the MFB, with 3
rats having electrode placements just outside of the MFB (2 from the 0 mg/mL vehicle control and
1 from the 24 mg/mL vapor group).
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